###### Key questions

What is already known about this subject?
=========================================

-   There is a complex interplay between heart failure and body composition with neurohormonal activation and endothelial dysfunction

-   Cardiac cachexia affects all body composition components and is driven by a procatabolic state and is a predictor of poor heart failure outcomes.

-   Cardiac resynchronisation therapy (CRT) causes reverse cardiac remodelling improving both morbidity and mortality but the impact of CRT on body composition in these patients is unclear.

What does this study add?
=========================

-   This is the first prospective pilot study to examine body composition parameters both before and after CRT implantation.

-   It suggests a trend towards reduction in fat mass in CRT non-responders.

-   The association between left ventricular geometry and fat mass relative change following CRT suggests that the increased measured fat mass may be linked to reverse cardiac remodelling.

How might this impact on clinic practice?
=========================================

-   Successful CRT response appears to be linked to maintenance of fat mass status at implant and the neurohormonal system appears integral to this.

-   Knowledge of the relationship of body composition and CRT may help better identify those who are likely to benefit from CRT.

Introduction {#s1}
============

There is a complex interplay between heart failure (HF), body composition and metabolism.[@R1] Development of HF causes neurohormonal activation, a proinflammatory state and endothelial dysfunction favouring a procatabolic state,[@R2] which is heavily influenced by body composition.[@R1] Obesity makes development of HF more likely,[@R4] however, the presence of adiposity is protective against HF progression.[@R5] This observation has been termed the 'obesity paradox'.[@R4] Higher adiposity is also inversely related to neurohormonal activation.[@R6] Sarcopenia is associated with a proinflammatory state[@R7] and increased neurohormonal signalling.[@R6] Cardiac cachexia affects all body composition components and is driven by a procatabolic state; it is a predictor of poor HF outcomes.[@R2] Cardiac resynchronisation therapy (CRT) causes reverse cardiac remodelling improving both morbidity and mortality.[@R8] Cai *et al* [@R9] observed being overweight/obese predicted CRT response and improved 6-month survival suggesting body composition may be impacted and/or altered by CRT. Baseline body composition parameters may also be predictive of CRT response. The aim of our proof-of-concept study was to evaluate body composition in patients with HF both before and after CRT implantation.

Methods {#s2}
=======

Patient population {#s2-1}
------------------

We performed a prospective pilot study of consecutive patients with HF undergoing CRT meeting National Institute of Clinical Excellence (TA120) implant criteria[@R10] between September 2014 and December 2015. The study was conducted in accordance with the Declaration of Helsinki and all patients provided informed consent. Air displacement plethysmography (ADP) was performed preimplant, 6 weeks and 6 months postimplant. All had New York Heart Failure Assessment (NYHA), 6 min walk test, transthoracic echocardiography, Minnesota Living with HF Questionnaire (MLHFQ), resting 12-lead ECG and blood sampling, including N-terminal probrain natriuretic peptide (NT-pro-BNP). All our elective implants were performed as same-day procedures as reported previously.[@R11] All underwent echocardiography (Vivid 7, GE Healthcare, Horten, Norway) for left ventricular (LV) assessment by a nationally accredited operator on the same machine with measurements analysed offline. Whole body ADP (BOD-POD-Life Measurement, Concord, California, USA) reliably and reproducibly measures body composition comparable with traditional methods.[@R12] Participants were fasted, rested 2 hours pretest and had height/weight measurements taken. All entered BOD-POD wearing a lycra swim cap and underwear only for measurement standardisation; two serial measurements were averaged. Where measurements varied significantly a third test was performed. The primary outcome was functional response status defined as those who survived, did not undergo heart transplantation and achieved two out of three response criteria (↓\>1 NYHA, ↑[\>]{.ul}10% 6 MWT distance, ↓MLHFQ score \>5) at 6-month follow-up.

Statistical analysis {#s2-2}
--------------------

Statistical analysis was performed using SPSS, V.22.0 (IBM). Categorical variables were reported as frequency/percentages. Categorical data were compared using X^2^/Fisher's exact tests. Normally distributed continuous data were reported as mean±SD and analysis performed using independent t-tests. Non-normally distributed data were reported as median (+full range) and compared using Mann-Whitney U test. Variation in continuous variables over three time periods was analysed using either one-way analysis of variance/Friedman test. Mixed between-within subjects analysis of variance was used to compare variation in body composition data in functional responders/non-responders over 6 months. Pearson (parametric) or Spearman's rank (non-parametric) estimators were performed between change in body composition and functional/echocardiographic and neurohormonal parameters; p\<0.05 was considered significant.

Results {#s3}
=======

Twenty-seven patients were recruited; 25 had baseline body composition assessment (one unable to enter BOD-POD, one had significant erroneous measurements despite repeated attempts). Baseline characteristics are shown in [table 1](#T1){ref-type="table"}. Three patients were unable to have 6-month body composition assessment (one death during follow-up and two not well enough for BOD-POD assessment). The first follow-up was at 1.7 months (SD: 0.3 months) and final visit was 5.8 months (SD: 0.5 months) post-CRT. Baseline characteristics were no different between responders versus non-responders, including all body composition parameters.

###### 

Baseline characteristics of the cohort

                                            Total cohort n=25      Responders n=12        Non-responders n=11    P value
  ----------------------------------------- ---------------------- ---------------------- ---------------------- ---------
  **Demographics**                                                                                               
   Age (years, mean±SD)                     73.4±10.0              68.1±14.4              76.0±7.4               0.19
   Male (n,%)                               23 (92.0%)             12 (100.0%)            9 (81.8%)              0.42
  **Device**                                                                                                     
   CRT-D (n,%)                              18 (72.0)              8 (66.7)               9 (81.8)               0.73
   Upgrade (n,%)                            9 (36.0)               2 (16.7)               7 (63.6)               0.06
  **Aetiology**                                                                                                  
   Ischaemic (n,%)                          16 (64.0)              6 (50.0)               8 (72.7)               0.49
   Non-ischaemic (n,%)                      9 (36.0)               6 (50.0)               3 (27.3)               
  **Comorbidities**                                                                                              
   Diabetes mellitus (n,%)                  6 (24.0)               2 (16.7)               4 (36.4)               0.55
   CKD (n,%)                                13 (52.0)              7 (58.3)               6 (54.5)               1.00
  NYHA (n,%)                                                                                                     
   II                                       10 (43.5)              5 (41.7)               5 (45.5)               0.52
   III                                      12 (52.2)              7 (58.3)               5 (45.5)               
   IV                                       1 (4.3)                0 (0.0)                1 (9.1)                
  ECG                                                                                                            
   AF (n,%)                                 9 (36.0)               4 (33.3)               4 (36.4)               1.00
   LBBB (n,%)                               17 (68.0)              9 (75.0)               6 (54.5)               0.56
   QRS (ms, median, range)                  162(120--212)          168 (138--212)         160 (138--194)         0.60
   6MWT (M, mean±SD)                        252.6±132.0            291.9±133.3            215.3±147.4            0.29
   **QOL score** (median, range)            48.0 (8.0--85.0)       55.5 (9.0--85.0)       29.0 (8.0--68.0)       0.11
  **Laboratory tests**                                                                                           
   eGFR (ml/min/1.73 m^2^, median, range)   52.0 (25.0--130.0)     52.5 (25.0--130.0)     52.0 (26.0--79.0)      0.61
   NT-pro-BNP (pmol/L, median, range)       267.0 (75.0--4138.0)   237.0 (75.0--4138.0)   273.0 (133.0--547.0)   0.33
  **Medications**                                                                                                
   ACEi/ARB (n,%)                           25 (100.0)             12 (100.0)             11 (100.0)             1.00
   BB (n,%)                                 21 (84.0)              10 (83.3)              10 (90.9)              0.62
   MRA (n,%)                                14 (56.0)              7 (58.3)               5 (45.5)               0.38
  **Echocardiography\***                                                                                         
   LVESV (mL, median, range)                125.8 (62.9--268.7)    136.7 (80.7--268.7)    110.9 (62.9--169.4)    0.29
   LVESV_BSA(mL, median, range)             58.9 (38.7--128.0)     66.1 (42.7--128.0)     59.1 (38.7--85.8)      0.35
   LVEF (%, median, range)                  25.6 (9.7--35.4)       24.4 (10.0--34.4)      28.6 (9.7--35.4)       0.40
  **Body composition**                                                                                           
   BMI (kg/m^2^, median, range)             28.7 (22.4--41.9)      29.3 (22.4--37.3)      27.8 (23.9--40.8)      0.85
   FM (kg, median, range)                   31.4 (18.1--61.2)      31.3 (19.3--56.4)      29.7 (18.1--58.7)      0.81
   Relative FM (median, range)              0.38 (0.23--0.54)      0.35 (0.28--0.50)      0.42 (0.23--0.54)      0.29
   Lean mass (kg, median, range)            52.3 (30.9--73.3)      52.6 (40.3--73.3)      50.5 (30.9--62.5)      0.48
   Waist (cm, median, range)                98.2 (84.6--131.0)     97.5 (84.6--120.8)     98.2 (85.0--114.5)     0.79

\*Based on available data

ACEi, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ARB, ACE receptor antagonist; BMI, body mass index; BNP, brain natriuretic peptide; BSA, body surface area; CKD, chronic kidney disease; CRT, cardiac resynchronisation therapy; eGFR, estimated glomerular filtration rate; FM, fat mass; LBBB, Left bundle branch block; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; 6MWT, 6 min walk test; NT-pro-BNP, N-terminal probrain natriuretic peptide; NYHA, New York Heart Failure Assessment; QOL, quality of life; QRS, QRS width on ECG.

The effect of CRT on cardiac function and body composition is shown in [table 2](#T2){ref-type="table"}. There was significant improvement in MLHFQ scores and decrease in QRS duration post CRT-implant. Total and percentage fat mass showed reduction trend 6 months post-CRT with improvement trend in LV ejection fraction) and decrease in LV end-systolic volume (LVESV).

###### 

The effect of crt on cardiac function and body composition

                                           Baseline               6 weeks                6 months               P value
  ---------------------------------------- ---------------------- ---------------------- ---------------------- ---------
  **Clinical, functional, laboratory\***                                                                        
  QOL score (median, range)                48.0 (8.0--85.0)       33.5 (0.0--73.0)       23.5 (0.0--0.83)       0.06
  QRS (ms, median, range)                  162(120--212)          145 (102--194)         159 (112--214)         0.02
  6MWT (M, mean±SD)                        252.6±132.0            277.1±145.2            242.4±178.8            0.29
  eGFR (ml/min/1.73 m^2^, median, range)   52.0 (25.0--130.0)     47.0 (24.0--105.0)     52.7 (20.0--90.0)      0.34
  NT-pro-BNP (pmol/L, median, range)       267.0 (75.0--4138.0)   236.5 (27.0--3848.0)   272.5 (15.0--1690.0)   0.87
  **Body composition (median, range**)                                                                          
  BMI (kg/m2)                              28.7 (22.4--41.9)      28.5 (22.0--34.4)      28.0 (22.4--35.7)      0.39
  Fat mass (kg)†                           31.4 (18.1--61.2)      29.0 (18.9--61.2)      29.1 (18.6--50.3)      0.12
  Relative fat mass†                       0.38 (0.23--0.54)      0.34 (0.25--0.51)      0.39 (0.28--0.52)      0.09
  Lean mass (kg)†                          52.3 (30.9--73.3)      53.9 (31.9--75.0)      50.5 (31.9--75.0)      0.19
  Waist circumference (cm)†                98.2 (84.6--131.0)     99.3 (76.0--119.4)     100.1 (78.9--120.9)    0.53
  **Echocardiography‡**                                                                                         
  LVESV (mL, median, range)                125.8 (62.9--268.7)    112.7 (52.8--210.8)    95.2 (57.8--315.6)     0.26
  LVESV_BSA(mL, median, range)             58.9 (38.7--128.0)     56.8 (28.2--118.7)     49.5 (30.6--131.5)     0.26
  LVEF (%, median, range)                  25.6 (9.7--35.4)       29.4 (13.6--43.6)      32.7 (14.4--41.7)      0.14

\*Based on patients able to have clinical, functional and laboratory assessments (baseline=25, 6 weeks=24, 6 months=22),

†Based on participants able/available to have BOD-POD assessment (baseline=25, 6 weeks=23, 6 months=20).

‡Based non complete series of echocardiograms with biplane measurements.

BMI, body mass index; BOD POD, trade name of the device used; BSA, body surface area; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; 6MWT, 6 min walk test; NT-pro-BNP, N-terminal probrain natriuretic peptide; QOL, quality of life.

Changes over time in body composition for functional responders and non-responders were analysed. [Online supplementary A](#SP1){ref-type="supplementary-material"} shows changes in body composition after CRT implantation with no difference between responders versus non-responders and no change in body composition over 6 months. However, a trend for higher relative fat mass at baseline for non-responders and large decrease 6 weeks post-CRT compared with responders was noted. After 6 weeks relative fat mass in non-responders returned to levels similar to baseline at 6 months. Responders had minimal variation over the three observation points and had lower relative fat mass than non-responders. There was a trend towards difference between responders and non-responders over time for fat mass.
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[Online supplementary B](#SP1){ref-type="supplementary-material"} shows the strongest associations between body composition and cardiac function post-CRT implant. A strong inverse correlation was noted between LVESV index and relative fat mass over the first 6 weeks and medium inverse correlation between fat mass and NT-pro-BNP. There was medium association between fat mass and estimated glomerular filtration rate (eGFR), r=0.41, p=0.06, which trended towards significance at 6 weeks. Long term, the strongest inverse correlation was between fat mass and eGFR. A significant association was also observed between eGFR and fat-free mass (r=0.47, p=0.04) at 6 months post-CRT implant.

Discussion {#s4}
==========

This is the first study examining body composition before and after CRT implantation in patients with HF and functional response, with association between fat mass and LV geometry noted post-CRT implant. Short-term changes in LVESV/LVESV index were strongly inversely correlated with fat-mass and relative fat mass 6 weeks post-CRT. Fat-free mass (lean mass) decreased post-CRT, fat mass and relative fat mass decreased at first follow-up, returning to baseline at 6 months; this trend was driven primarily by non-responders.

There are currently no data evaluating reliability of ADP in HF.[@R12] ADP interprets body water as fat mass and it is likely that the changes noted may be the result of changes in body water content. Renal function, specifically eGFR, was inversely correlated with change in fat mass at 6 months, trending towards significance at 6-week follow-up.

The association between LV geometry and fat mass relative change following CRT suggests that the increased measured fat mass may be linked to reverse cardiac remodelling. The mechanism for this may be multifactorial and could be related to changes in body water content following CRT. The neurohormonal system may be implicated through reduction in circulating natriuretic peptides in the presence of increased adiposity.[@R1] Adipocytes are sensitive to natriuretic peptides, activating lipolysis and enhancing expression of brown adipocyte genes, increasing thermogenesis thereby favouring a procatabolic state in progressive HF.[@R3] Naturetic peptides are known to stimulate release of adipokines (specifically adiponectin and leptin), which increase energy utilisation and weight reduction.[@R3] Increased NT-pro-BNP immediately after CRT was associated with decreasing fat mass supporting the inverse association between natriuretic peptides and body mass index (BMI) (BMI/fat mass previously reported.[@R3] There are limited data on CRT and body composition; a retrospective study of 219 CRT patients evaluated initial BMI predicting response and cardiovascular outcomes at 6 months; they showed overweight/obese patients preimplant had better response and improved outcomes.[@R9]

Deterioration in renal function and presence of stage 3 chronic kidney disease consistently predicts poor outcomes post-CRT.[@R13] Progressive deterioration in eGFR is linked to adverse cardiac remodelling.[@R14] The inverse correlation between eGFR and fat mass at 6 months suggests increasing fat mass is associated with deteriorating renal function which is unusual as obesity is believed to preserve renal function.[@R4] There was no association between lean mass and BMI. Caution is advised interpreting these results as eGFR is calculated using the renal disease equation,[@R15] which uses body surface area as a parameter, meaning eGFR is not an independent variable.

Study limitations {#s4-1}
-----------------

Our study has several limitations. Our cohort size was small and may impact the findings. However, this was a proof-of-concept pilot study and our findings should generate further studies in larger cohorts. Two of our participants were unable to undergo BOD-POD assessment, which could introduce selection bias. ADP does not account for body water and measures it as fat mass, meaning patient oedema may impact study findings. Our study was unable to account for the presence of cardiac cachexia, which is known to be important in advancing HF.[@R1] Also, not all patients were able to have complete LV assessment by echocardiography due to body habitus.

Conclusion {#s5}
==========

This is the first prospective pilot study to examine body composition parameters both before and after CRT implantation. It suggests a trend towards reduction in fat mass in CRT non-responders. Successful CRT response appears to be linked to maintenance of fat mass status at implant. The neurohormonal system appears integral to this.
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